Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Change in Account Payables (2017 - 2025)

Historic Change in Account Payables for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $13.0 million.

  • Arcus Biosciences' Change in Account Payables rose 140000.0% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.0 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2024, which is 40000.0% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Change in Account Payables is $13.0 million, which was up 140000.0% from $8.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Change in Account Payables registered a high of $13.0 million during Q3 2025, and its lowest value of -$19.0 million during Q2 2023.
  • Over the past 5 years, Arcus Biosciences' median Change in Account Payables value was $3.5 million (recorded in 2022), while the average stood at $1.6 million.
  • Per our database at Business Quant, Arcus Biosciences' Change in Account Payables skyrocketed by 178679.25% in 2022 and then plummeted by 57500.0% in 2023.
  • Over the past 5 years, Arcus Biosciences' Change in Account Payables (Quarter) stood at $424000.0 in 2021, then soared by 1786.79% to $8.0 million in 2022, then crashed by 75.0% to $2.0 million in 2023, then skyrocketed by 150.0% to $5.0 million in 2024, then skyrocketed by 160.0% to $13.0 million in 2025.
  • Its Change in Account Payables was $13.0 million in Q3 2025, compared to $8.0 million in Q2 2025 and $3.0 million in Q1 2025.